Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
The former general counsel for Bio-Rad accused the company and CEO Norman Schwartz of firing him in retaliation for blowing the whistle on alleged violations of the Foreign Corrupt Practices Act in China.
Sanford Wadler, who was general counsel and executive vice president when Bio-Rad sacked him in June 2013, alleged that he was fired right before the company was slated to present findings from its investigation into bribery in Russia, Thailand and Vietnam. Bio-Rad later agreed to a $55 million settlement with the U.S. Justice Dept. and the Securities & Exchange Commission, which found that it paid $7.5 million in bribes to drum up some $35 million in profits. Read more
Arch Therapeutics said it won approval for a European safety-and-efficacy study of its AC5 surgical hemostat in bleeding wounds incurred during dermatology procedures.
Framingham, Mass.-based Arch said the endpoints for the single-blinded study of up to 50 patients include time to hemostasis and product-related adverse effects at 30 days. One arm of the trial will include patients taking blood thinning drugs, the company said. Read more
Babak Parviz says he sold Google a vision of an autonomous surgical robot in 2010. His vision put the patient under the knife of a completely autonomous surgeon which would bring with it lightning-fast reaction times and super-human dexterity, along with the ability to be mass produced.
That vision, Parviz says, could be on the horizon with Verily and Johnson & Johnson’s newly launched Verb Surgical, according to an interview with Backchannel. Read more